16 Sep '21
Sight Sciences Files Lawsuit Against Ivantis for Patent Infringement
Sight Sciences Seeks Injunction Related to Hydrus® Microstent’s Infringement MENLO PARK, Calif., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ: SGHT) today announced that it filed a lawsuit in the United States District Court in Delaware against Ivantis, Inc.
24 Aug '21
Sight Sciences, Pioneering the Development of the Standalone MIGS Market, Announces Publication of Favorable Two-Year Outcomes of Standalone Use of the OMNI® Surgical System in Mild to Moderate Open-Angle Glaucoma
Real-world data published in Clinical Ophthalmology show the safety, efficacy, and durability of effect of OMNI for use in a standalone procedure to reduce intraocular pressure and medication burden MENLO PARK, Calif., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc .
12 Aug '21
Sight Sciences Reports Second Quarter 2021 Financial Results
MENLO PARK, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today reported financial results for the quarter ended June 30,
14 Jul '21
Sight Sciences Announces Pricing of Initial Public Offering
MENLO PARK, Calif. , July 14, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. , a growth-stage medical device company focused on the development and commercialization of proprietary devises that target the underlying causes of the world’s most prevalent eye diseases, today announced the pricing of